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The data presented here are related to the research paper
entitled “Thrombin induces protease-activated receptor 1 sig-
naling and activation of human atrial fibroblasts and dabiga-
tran prevents these effects” (Altieri et al., 2018) [1]. Data show
that silencing of protease-activated receptor 1 (PAR1) prevents
the activation of Fib isolated from atrial appendages of patients
without atrial fibrillation (AF), as assessed by immuno-
fluorescence for α-smooth muscle actin (αSMA) and Picro-
Sirius red staining. Moreover, it is reported that primary
atrial Fib obtained from two subjects with permanent AF
express PAR1 and PAR2 and display enhanced αSMA immu-
noreactivity and collagen synthesis in response to thrombin,vier Inc. This is an open access article under the CC BY license
.ijcard.2018.05.033












P. Altieri et al. / Data in Brief 19 (2018) 925–931926but not to dabigatran-bound thrombin, alike Fib from non-
fibrillating atria.
& 2018 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Specifications Tableubject area Health science
ore specific subject area Experimental cardiology
Atrial fibrillation; cardiac fibroblasts
ype of data Text file, figures
ow data was acquired Microscope (Leica DM2000 fluorescence microscope and Olympus BX50
light microscope, coupled to Leica Application Suite software)
ata format Analyzed
xperimental factors Primary human atrial fibroblasts untreated or exposed to thrombin,
dabigatran-bound thrombin or dabigatran alone
xperimental features Silencing of PAR1 attained by small interfering RNA-based knockdown
Protein expression analyzed by immunofluorescence and western blot, col-
lagen synthesis by Picro-Sirius red staining, and PAR1 expression by RT-PCRata source location Laboratory of Cardiovascular Biology, Department of Internal Medicine,
University of Genova, Genova, Italyata accessibility Data are available within the article
elated research article “Thrombin induces protease-activated receptor 1 signaling and activa-
tion of human atrial fibroblasts and dabigatran prevents these effects” by
Altieri P, Bertolotto M, Fabbi P, Sportelli E, Balbi M, Santini F, Brunelli C,
Canepa M, Montecucco F, Ameri P.Value of the data
 Data expand on the knowledge of thrombin actions on human cells.
 Data may provide the background for further studies about PAR1-mediated effects of thrombin on
human atrial fibroblasts in both the absence and presence of AF.
 Data may serve as reference for silencing of target genes in primary human atrial fibroblasts.1. Data
Data confirm that thrombin cleaves PAR1 of primary human atrial Fib, this effect being antag-
onized by the direct thrombin inhibitor dabigatran (Fig. 1A), and show that small interfering RNA
(siRNA)-based knockdown effectively reduces the amount of PAR1 protein, regardless of the presence
of dabigatran (Fig. 1B–C). While thrombin, but not dabigatran-inhibited thrombin, substantially
increased the expression of αSMA and the synthesis of collagen in control conditions, these effects
were not observed when PAR1-silenced cells were incubated with thrombin (Figs. 2 and 3).
To integrate the data presented above, which were obtained with cells harvested from the atrial
appendages of patients without AF, atrial Fib were also collected from 2 subjects who instead suffered
from permanent AF. Fib from fibrillating atria expressed PAR1 and PAR2 (1/2̂DCt for PAR1 ¼ 0.008 in
both cases, 1/2̂DCt for PAR2 ¼ 0.001–0.004); mRNA for PAR3 was very low (1/2̂DCt ¼ 0.00003), and
that for PAR4 not detectable.
Fig. 1. (A) Representative pictures of primary human atrial Fib from patients without AF, immunostained for PAR1 after
no treatment or exposure to thrombin (Th), dabigatran followed by thrombin (Dab þ Th), or dabigatran alone (Dab).
(B) Representative pictures of immunofluorescence for PAR1 in primary Fib from non-fibrillating atria, transfected with
negative control siRNA (siCTR) or siRNA targeting human PAR1 (siPAR1), with or without subsequent incubation with
dabigatran (Dab). Magnification is 200 , bars indicate 50 μm. (C) Western blot for PAR1, confirming the knockdown of PAR1
protein after transfection with siPAR1, but not siCTR.
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incubation with thrombin (Fig. 4). Like for Fib from non-fibrillating atria [1], dabigatran counteracted
the accumulation of αSMA and collagen stimulated by thrombin (Fig. 4).2. Experimental design, materials, and methods
2.1. Materials and reagents
Unless otherwise specified, materials and reagents were purchased from Sigma-Aldrich (Munich,
Germany).
2.2. Cells and experimental design
Primary Fib were isolated from patients who underwent elective cardiac surgery: 8 without AF [1]
and 2 with permanent AF, a 80 year old man with diabetes mellitus and a 78 year old woman with
hypertension and dyslipidemia, both affected by valvular disease. Briefly, right atrial appendages were
collected when the venous cannula was placed for extracorporeal circulation, fragmented and
enzymatically digested for 45min at 37 °C with 1mg/mL collagenase II (Worthington Biochemical
Corporation, Lakewood, NJ, USA) in Ca2þ- and Mg2þ-free PBS added with 0.2% BSA. At the end of the
incubation, collagenase was neutralized by adding DMEM/F12 with 10% FBS and the resulting solution
was filtered through a 70 μm nylon filter (BD Biosciences, Milano, Italy) and centrifuged for 10min at
1400 rpm. The pellet was re-suspended in DMEM/F12 with 10% FBS and placed into a Petri dish. After
3 h, mostly Fib adhered to the bottom of the dish and non-adherent non-Fib cells were removed. Fib
were then grown in Endothelial Growth Medium-2 (EGM-2; Lonza, Walkersville, MD, USA) to limit
the tendency to spontaneous activation in response to culturing [2].
Cells were passaged at 70% confluence and used for experiments from passage 2 to passage 5. After
washing twice with Endothelial Basal Medium-2 (EBM; Lonza), atrial Fib were treated with 1nM thrombin
(human α-thrombin at 3117 NiH U/mL specific activity; Enzyme Research Laboratories, South Bend, IN,
USA), 500 nM dabigatran (Boehringer Ingelheim International GmbH, Biberach, Germany) for 30min and
then 1nM thrombin, or 500nM dabigatran alone. The duration of the incubation with thrombin was 15
Fig. 2. Representative images (A) and quantification (B) of immunofluorescence for αSMA in primary human atrial Fib left
untreated (CTR), incubated with thrombin (Th) and/or dabigatran (Dab), or transfected with a control (siCTR) or a PAR1-
targeting (siPAR1) siRNA with or without subsequent exposure to Th or Dab as indicated. Fib were obtained from subjects with
no history of AF. Magnification 200 , bars 50 μm. Data in B are from three independent replicates and were compared by the
Kruskal-Wallis test.
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were performed in EBM-2.
The study was approved by the local Ethics Committee and patients gave written informed
consent to participate.2.3. PAR1 silencing
Fib were seeded in 8-well chamber slides at a number of 5000 cells/well in antibiotic-free EGM-2,
allowed to adhere overnight, and then transfected with Silencer Select Validated siRNA targeting human
PAR1 (Ambion, Austin, TX, USA) or Silencer Negative Control #1 siRNA (ThermoFisher Scientific, Waltham,
MA, USA) at a final concentration of 5 pMol, using Lipofectamine RNAiMAX (Invitrogen, ThermoFisher
Scientific) as transfection reagent. After 24h, the siRNA-lipofectamine solution was replaced with EGM-2.
After another 24 h, cells were washed with PBS and exposed to thrombin, dabigatran for 30min and then
Fig. 3. Primary atrial Fib from subjects without AF were left untreated (CTR), exposed to thrombin (Th) and/or dabigatran
(Dab), or transfected with a control (siCTR) or a PAR1-targeting (siPAR1) siRNA with or without subsequent incubation with Th
or Dab. At the end of treatments, cells were stained with Picro-Sirius red. Representative images of the staining in conventional
and polarized light microscopy are given in (A) and (B), respectively, while quantification of the red signal in conventional light
microscopy is presented in (C). Magnification is 200 and bars correspond to 50 μm. Data in the graph are from three
independent replicates and were compared by using the Kruskal-Wallis test.
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Fig. 4. Representative images of immunofluorescence for αSMA (upper line) and Picro-Sirius red staining (lower line) of primary
human atrial Fib isolated from the 2 patients with AF included in this study, after no treatment (CTR) or incubation with thrombin
(Th) and/or dabigatran (Dab).
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PAR1 levels and 72h for evaluation of αSMA and collagen expression.2.4. Analysis of PAR1 expression
RT-PCR for F2R (encoding PAR1) was carried out with Taqman Gene Expression Assay MTO from Life
Technologies after extracting total RNA by means of the Quick-RNA MiniPrep kit (Zymo Research, Irvine,
CA, USA) and reverse-transcribing to cDNAwith iScript Reverse Trascription Supermix RT-qPCR (Bio-Rad).
Samples were amplified by using an EagleTaq Universal master mix (Roche Diagnostics GmbH, Man-
nheim, Germany) on a CFX96 Touch RT-PCR Detection System (Bio-Rad). The expression of the genes of
interest was normalized against that of RPLP0 and analyzed with the comparative DDCt method. Assays
ID were Hs00169258 and Hs99999902 for F2R and RPLP0, respectively.
Levels of PAR1 protein were investigated by immunofluorescence of Fib grown on chamber slides
to 70% confluence. Cells were incubated for 1 h with a mouse monoclonal primary antibody against
Arg27-Thr102 and Ser375-Thr425 of human PAR1 (clone 731115, R&D Systems, Minneapolis, MN,
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Scientific). Nuclei were stained with DAPI (ThermoFisher Scientific).
PAR1 protein expression was also studied by Western blotting with overnight incubation with the
mouse monoclonal antibody against Arg27-Thr102 and Ser375-Thr425 of human PAR1, followed by
incubation with HRP-conjugated anti-mouse secondary antibody (Santa Cruz Biotechnology, Dallas,
TX, USA). Protein bands were visualized with the Clarity Western ECL Substrate (Bio-Rad, Segrate,
Milano, Italy).
2.5. Analysis of fibroblast activation and collagen secretion
Fib were cultured in 8-well chamber slides, treated for 48 or 72 h as described in Sections 2.2 and
2.3, and fixed in  20 °C methanol for 1min.
Expression of the marker of Fib activation, αSMA, was assessed by immunofluorescence with a
mouse monoclonal anti-human αSMA antibody (clone 1A4, Dako, Denmark).
Collagen production was evaluated by Picro-Sirius red staining. Fixed cells were incubated for 1 h
with a staining solution made of Sirius red (0.1%, Sigma) dissolved in a saturated aqueous solution of
picric acid (1.3% in water, Sigma), washed three times with 0.1% acetic acid, and dehydrated with
ethanol followed by xylene.
To quantify αSMA and collagen levels, random images were taken from at least 5 independent fields for
each condition by using a Leica DM2000 fluorescence microscope (Leica Microsystems GmbH, Wetzlar,
Germany) and a Olympus BX50 light microscope (Olympus, Tokyo, Japan), respectively, coupled to a CCD
high resolution cooled camera and the Leica Application Suite software (Leica Microsystems). Signal
intensity was thenmeasured with the ImageJ analysis software (National Institutes of Health, Bethesda, MD,
USA) [3].
2.6. Statistical analysis
Data are presented as mean 7 SEM of fold change vs. control and were compared by the Kruskal-
Wallis test with GraphPad Prism Version 6.0a (GraphPad Software). A P value o0.05 was considered
statistically significant.Acknowledgements
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